siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury

Bruce A. Molitoris, Pierre C. Dagher, Ruben M. Sandoval, Silvia B. Campos, Hagit Ashush, Eduard Fridman, Anat Brafman, Alexander Faerman, Simon J. Atkinson, James D. Thompson, Hagar Kalinski, Rami Skaliter, Shai Erlich, Elena Feinstein

Research output: Contribution to journalArticle

196 Scopus citations

Abstract

Proximal tubule cells (PTCs), which are the primary site of kidney injury associated with ischemia or nephrotoxicity, are the site of oligonucleotide reabsorption within the kidney. We exploited this property to test the efficacy of siRNA targeted to p53, a pivotal protein in the apoptotic pathway, to prevent kidney injury. Naked synthetic siRNA to p53 injected intravenously 4 h after ischemic injury maximally protected both PTCs and kidney function. PTCs were the primary site for siRNA uptake within the kidney and body. Following glomerular filtration, endocytic uptake of Cy3-siRNA by PTCs was rapid and extensive, and significantly reduced ischemia-induced p53 upregulation. The duration of the siRNA effect in PTCs was 24 to 48 h, determined by levels of p53 mRNA and protein expression. Both Cy3 fluorescence and in situ hybridization of siRNA corroborated a short t1/2 for siRNA. The extent of renoprotection, decrease in cellular p53 and attenuation of p53-mediated apoptosis by siRNA were dose- and time-dependent. Analysis of renal histology and apoptosis revealed improved injury scores in both cortical and corticomedullary regions. siRNA to p53 was also effective in a model of cisplatininduced kidney injury. Taken together, these data indicate that rapid delivery of siRNA to proximal tubule cells follows intravenous administration. Targeting siRNA to p53 leads to a dose-dependent attenuation of apoptotic signaling, suggesting potential therapeutic benefit for ischemic and nephrotoxic kidney injury.

Original languageEnglish (US)
Pages (from-to)1754-1764
Number of pages11
JournalJournal of the American Society of Nephrology
Volume20
Issue number8
DOIs
StatePublished - Aug 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Nephrology

Cite this

Molitoris, B. A., Dagher, P. C., Sandoval, R. M., Campos, S. B., Ashush, H., Fridman, E., Brafman, A., Faerman, A., Atkinson, S. J., Thompson, J. D., Kalinski, H., Skaliter, R., Erlich, S., & Feinstein, E. (2009). siRNA targeted to p53 attenuates ischemic and cisplatin-induced acute kidney injury. Journal of the American Society of Nephrology, 20(8), 1754-1764. https://doi.org/10.1681/ASN.2008111204